Association of longitudinal cardiac troponin trajectory with adverse events in patients with cardiac sarcoidosis

• Published in: International journal of cardiology Vol. 389; p. 131268
• Main Authors: Kazui, Sho, Takenaka, Sakae, Nagai, Toshiyuki, Kato, Yoshiya, Komoriyama, Hirokazu, Kobayashi, Yuta, Takahashi, Akinori, Kamiya, Kiwamu, Sato, Takuma, Tada, Atsushi, Yasui, Yutaro, Nakai, Michikazu, Sato, Takahiro, Tsujino, Ichizo, Konno, Satoshi, Anzai, Toshihisa
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15.10.2023
• Subjects: Cardiac sarcoidosis; Cardiac troponin T; Longitudinal measurement; Cardiac sarcoidosis; Longitudinal measurement; Cardiac troponin T
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2023.131268

Although high-sensitivity cardiac troponins may be sensitive and easily repeatable markers of disease activity in patients with cardiac sarcoidosis (CS), the association between longitudinal cardiac troponin trajectory and adverse events remains unclear. This study aimed to clarify whether longitudinal cardiac troponin levels were associated with adverse events in patients with CS. We examined 63 consecutive CS-initiated prednisolone (PSL) patients with available longitudinal high-sensitivity cardiac troponin T (cTnT) data between December 2013 and March 2023. The area under the cTnT trajectory, which reflected cumulative cTnT release, was calculated to assess the association between longitudinal cTnT levels and adverse events. Patients were divided into two groups according to the median area under the cTnT trajectory per month. The primary outcome was a composite of sustained ventricular tachycardia or fibrillation, worsening heart failure, and sudden cardiac death (SCD). In total, 463 cTnT measurements were collected over a median follow-up period of 30.4 (interquartile range [IQR] 15.6–34.2) months. The primary outcome was observed in 12 (19%) patients. A higher area under the cTnT trajectory was significantly associated with an increased incidence of the primary outcome (P = 0.027), while cTnT levels before and one month after initiation of PSL, and these changes were not related to adverse events (P = 0.179, 0.096, and 0.95, respectively). Longitudinal cTnT trajectory following PSL initiation was associated with adverse cardiac events in patients with CS, suggesting that longitudinal measurement of cTnT would be useful for the early identification of high-risk patients. •Longitudinal cardiac troponin T (cTnT) trajectory was associated with adverse events in cardiac sarcoidosis (CS).•cTnT levels before and one month after initiation of PSL were not significantly related to the events.•These findings indicate the importance of assessing longitudinal cTnT levels for risk stratification in patients with CS.